Steven Steinhubl

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Adenosine diphosphate receptor blockade in coronary intervention
    Steven R Steinhubl
    Department of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599 7075, USA
    J Invasive Cardiol 16:7S-10S. 2004
  2. ncbi What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steven Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Building, Chapel Hill, NC 27599 7075, USA
    Am Heart J 145:971-8. 2003
  3. ncbi Antiplatelet therapy: aspirin
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, 349 Burnett - Womack Building, Chapel Hill, NC 27599, USA
    J Invasive Cardiol 15:11B-16B; discussion 16B. 2003
  4. ncbi Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
  5. ncbi The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention
    Robert V Kelly
    University of North Carolina, Chapel Hill, North Carolina, USA
    J Invasive Cardiol 18:115-9. 2006
  6. ncbi Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0284, USA
    Am Heart J 154:3-11. 2007
  7. ncbi Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
  8. ncbi Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils
    Guohong Li
    Carolina Cardiovascular Biology Center, The University of North Carolina, Chapel Hill, USA
    Arterioscler Thromb Vasc Biol 27:1850-6. 2007
  9. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
  10. ncbi Variable response to antiplatelet therapy: what does it mean to clinicians?
    Nezar Falluji
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, USA
    Cleve Clin J Med 74:49-55. 2007

Collaborators

Detail Information

Publications64

  1. ncbi Adenosine diphosphate receptor blockade in coronary intervention
    Steven R Steinhubl
    Department of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599 7075, USA
    J Invasive Cardiol 16:7S-10S. 2004
    ..This article reviews data from recent and ongoing studies that address these issues...
  2. ncbi What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steven Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Building, Chapel Hill, NC 27599 7075, USA
    Am Heart J 145:971-8. 2003
    ..This review aimed to answer how long after PCI with a stent patients are at risk for recurrent thrombotic events and what the optimal way to prevent them is...
  3. ncbi Antiplatelet therapy: aspirin
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, 349 Burnett - Womack Building, Chapel Hill, NC 27599, USA
    J Invasive Cardiol 15:11B-16B; discussion 16B. 2003
  4. ncbi Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
    ..Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied...
  5. ncbi The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention
    Robert V Kelly
    University of North Carolina, Chapel Hill, North Carolina, USA
    J Invasive Cardiol 18:115-9. 2006
    ..Randomization to early- and long-term clopidogrel was associated with even further improvements in those with increasing BMI...
  6. ncbi Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0284, USA
    Am Heart J 154:3-11. 2007
    ....
  7. ncbi Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
    ....
  8. ncbi Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils
    Guohong Li
    Carolina Cardiovascular Biology Center, The University of North Carolina, Chapel Hill, USA
    Arterioscler Thromb Vasc Biol 27:1850-6. 2007
    ..CONCLUSIONS: Adjuvant therapy during PCI may have undesired effects on neutrophil activation, MPO release, and systemic inflammation...
  9. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  10. ncbi Variable response to antiplatelet therapy: what does it mean to clinicians?
    Nezar Falluji
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, USA
    Cleve Clin J Med 74:49-55. 2007
    ....
  11. ncbi Oral antiplatelet therapy for percutaneous coronary revascularization
    Hussam Hamdalla
    Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA
    Catheter Cardiovasc Interv 69:637-42. 2007
    ..This review will highlight these data as well as emphasize the gaps in our understanding. (c) 2007 Wiley-Liss, Inc...
  12. ncbi Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 7:S12-9. 2006
    ..All of this benefit was confined to the patients with elevated troponin levels. The data indicate that troponin can be used as a biomarker to identify patients most likely to benefit from the addition of a GP IIb/IIIa antagonist...
  13. ncbi Clopidogrel bisulfate: in ST-segment elevation myocardial infarction: a viewpoint by Steven R Steinhubl
    Steven R Steinhubl
    Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA
    Am J Cardiovasc Drugs 6:415-6. 2006
  14. ncbi Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy
    W H Wilson Tang
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 153:36-41. 2007
    ..The comparative prognostic values between NT-proBNP levels and left ventricular ejection fraction (LVEF) in the nonurgent PCI setting are unclear...
  15. ncbi Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  16. ncbi Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization
    Pranab Das
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky and the VA Medical Center, Lexington, Kentucky 40536-0200, USA
    J Invasive Cardiol 18:405-8. 2006
    ..However, in ESRD patients undergoing coronary revascularization, DES use is effective in reducing 9-month TVR and the composite of death, MI and TVR...
  17. ncbi Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 98:681-4. 2006
    ..A point-of-care assay can identify subjects who may recover platelet function before 5 days after discontinuation or, in contrast, have persistent PI despite discontinuation...
  18. ncbi Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44122, USA
    J Invasive Cardiol 19:287-90. 2007
    ..The relationship between target vessel revascularization (TVR) and ischemic events in patients treated with aspirin and clopidogrel or aspirin alone from 1 month to 1 year after PCI has not been studied...
  19. ncbi Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect
    Steven R Steinhubl
    Division of Cardiology, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Thromb Res 121:527-34. 2008
    ..As many individuals treated acutely with cangrelor will often be treated long-term with a thienopyridine, it is important to determine the effects of concurrent cangrelor and clopidogrel administration...
  20. ncbi Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
    John W Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    Circulation 118:1705-12. 2008
    ....
  21. ncbi Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
    Mark Y Chan
    Duke Clinical Research Institute, 2400 Pratt St, Terrace Level Room 0311, Durham, NC 27705, USA
    Circulation 117:2865-74. 2008
    ..REG1 consists of RB006 (drug), an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007 (antidote), the complementary oligonucleotide that neutralizes its anti-IXa activity...
  22. ncbi Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  23. ncbi Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use
    Marc S Sabatine
    Cardiovascular Division, Department of Medicine, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:910-7. 2008
    ..However, the need for clopidogrel pretreatment is debated in patients receiving a glycoprotein IIb/IIIa inhibitor (GPI)...
  24. ncbi The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
    Patricia J M Best
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 155:687-93. 2008
    ..Therapy with clopidogrel decreases adverse events in large patient populations. Therefore, we sought to determine the efficacy and safety of long-term clopidogrel therapy in patients with CKD...
  25. ncbi Vulnerable plaque intervention: State of the art
    John J Young
    Swedish Heart and Vascular Institute, Seattle, Washington 98122, USA
    Catheter Cardiovasc Interv 71:367-74. 2008
    ....
  26. ncbi Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  27. ncbi Platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Am Coll Cardiol 50:1822-34. 2007
    ....
  28. ncbi Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 S Limestone Ave, 326 Charles T Wethington Bldg, Lexington, KY 40536, USA
    J Thromb Thrombolysis 26:8-13. 2008
    ....
  29. ncbi Risk stratifying the acute coronary syndrome patient: a focus on treatable risk
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 8:S3-8. 2007
    ..Although the ACC/AHA Guidelines combine patients with unstable angina and NSTEMI, it is essential to evaluate troponin status in order to optimize patient outcomes and safety in the treatment of suspected ACS...
  30. ncbi The evolving algorithm concerning higher-risk PCI (TEACH-PCI). Introduction
    Steven R Steinhubl
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    Rev Cardiovasc Med 8:S1-2. 2007
  31. ncbi An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  32. ncbi Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial
    Jacqueline Saw
    Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 50:291-5. 2007
    ..The purpose of this study was to evaluate the potential impact of clopidogrel and statin interaction in a randomized, placebo-controlled trial with long-term follow-up...
  33. ncbi Incidence and prevention of ischemic stroke following myocardial infarction: review of current literature
    Monisha Dutta
    Department of Neurology, University of Kentucky, Lexington, KY 40536, USA
    Cerebrovasc Dis 22:331-9. 2006
    ..We discuss the incidence, pathophysiology, and management options of non-hemorrhagic stroke following a myocardial infarction...
  34. ncbi Clopidogrel-statin interaction: a mountain or a mole hill?
    Steven R Steinhubl
    Am Heart J 152:200-3. 2006
  35. ncbi Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention
    Jacqueline Saw
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:623-5. 2004
    ..4% vs 21.7%)...
  36. ncbi Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 110:994-8. 2004
    ..Despite significant pharmacological and mechanical advancements in PCI, uncertainty remains about the optimal activated clotting time (ACT) for prevention of ischemic or hemorrhagic complications...
  37. ncbi Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial
    James J Ferguson
    JAMA 292:45-54. 2004
    ..Enoxaparin is a safe and effective alternative to unfractionated heparin and the advantages of convenience should be balanced with the modest excess of major bleeding...
  38. ncbi Clopidogrel: how good is it and how does it work?
    Richard A Santa-Cruz
    Division of Cardiology, University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599 7075, USA
    Curr Cardiol Rep 6:264-8. 2004
    ....
  39. ncbi Antiplatelet effect of aspirin in patients with cerebrovascular disease
    Jay S Varanasi
    Stroke 35:e144-5. 2004
  40. ncbi Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes
    Jo E Rodgers
    Division of Pharmacotherapy, University of North Carolina, Chapel Hill 27599 7360, USA
    Expert Rev Cardiovasc Ther 1:507-21. 2003
    ....
  41. ncbi Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation
    James L Orford
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Am Heart J 147:463-7. 2004
    ..No patient died or sustained a myocardial infarction or stent thrombosis. CONCLUSIONS: The risk of bleeding may be increased in patients treated with aspirin, a thienopyridine, and warfarin early after PCI with stent placement...
  42. ncbi Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial
    Victor L Serebruany
    Sinai Center for Thrombosis Research, Johns Hopkins University, Sinai Hospital, Baltimore, MD 21215, USA
    Am Heart J 146:713-20. 2003
    ..We assessed antiplatelet properties of clopidogrel with aspirin (C+A) versus aspirin alone (A) in patients with CHF with heightened platelet activity...
  43. ncbi Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    Jacqueline Saw
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 108:921-4. 2003
    ....
  44. ncbi Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists
    Steven R Steinhubl
    Department of Medicine, University of North Carolina, Chapel Hill, 27599-7075, USA
    Coron Artery Dis 14:381-6. 2003
  45. ncbi Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested
    Victor L Serebruany
    Circulation 107:1568-9. 2003
  46. ncbi Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study)
    Michael R Tamberella
    Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA, USA
    Am J Cardiol 89:1429-31. 2002
  47. ncbi Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study
    Victor L Serebruany
    HeartDrug Research, LLC, Baltimore, MD, USA
    Arch Intern Med 164:2051-7. 2004
    ..We sought to address this issue prospectively by performing serial measurements of 19 platelet characteristics using conventional aggregometry, rapid analyzers, and flow cytometry...
  48. ncbi Risk reduction with long-term clopidogrel following percutaneous coronary intervention
    Steven R Steinhubl
    Eur Heart J 25:2169-70; author reply 2170-1. 2004
  49. ncbi Heparin-induced thrombocytopenia and cardiovascular diseases
    Pranab Das
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA
    Am Heart J 152:19-26. 2006
  50. ncbi Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough
    Steven R Steinhubl
    JAMA 295:1581-2. 2006
  51. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)...
  52. ncbi Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
    Steven R Steinhubl
    Linda and Jack Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
    J Am Coll Cardiol 47:939-43. 2006
    ..This study sought to determine the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (PCI) in patients enrolled in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial...
  53. ncbi The role of the platelet in the pathogenesis of atherothrombosis
    Steven R Steinhubl
    The Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington, Kentucky 40536 0284, USA
    Am J Cardiovasc Drugs 5:399-408. 2005
    ..Elucidation of the multiple mechanisms involved in platelet thrombus formation provides opportunities for selectively inhibiting the pathways most relevant to the pathophysiology of atherothrombosis...
  54. ncbi A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  55. ncbi Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction
    Ara M Maranian
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA
    Curr Cardiol Rep 4:313-9. 2002
    ..This review summarizes recently published trials using combination thrombolytic and GP IIb/IIIa receptor inhibitor therapy in the treatment of acute MI...
  56. ncbi Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 44:2133-6. 2004
    ..We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of pretreatment with a 600-mg loading dose of clopidogrel...
  57. ncbi Variability in platelet responsiveness to clopidogrel among 544 individuals
    Victor L Serebruany
    HeartDrug Research Laboratories, Osler Medical Building, 7600 Osler Drive, Towson, MD 21204, USA
    J Am Coll Cardiol 45:246-51. 2005
    ..We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population...
  58. ncbi Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, Maryland, USA
    Am J Cardiol 95:1218-22. 2005
    ..These findings should be considered when using combination antiplatelets, anticoagulant therapy, or both, with ASA, especially with the daily dose of >100 mg...
  59. ncbi Resistance to antiplatelet resistance is it justified?
    Steven R Steinhubl
    J Am Coll Cardiol 45:1757-8. 2005
  60. ncbi Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both?
    David J Moliterno
    JAMA 294:1271-3. 2005
  61. ncbi Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
    Steven R Steinhubl
    J Am Coll Cardiol 42:1336; author reply 1336-7. 2003
  62. ncbi Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development
    Neal S Kleiman
    Methodist DeBakey Heart Center, Houston, Texas, USA
    Platelets 19:239-51. 2008
    ....
  63. ncbi Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy
    Christopher M Thompson
    Department of Cardiology, Wilford Hall Medical Center, 2200 Bergquist Drive, Lackland Air Force Base, Texas 78236-5300, USA
    J Interv Cardiol 15:61-70. 2002
    ..This article discusses the details regarding the performance, advantages, disadvantages, and available data related to clinical use of each test in populations with coronary disease and patients treated with antiplatelet therapy...
  64. ncbi Platelets as mediators of inflammation
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, 900 South Limestone Avenue, 326 Charles T Wellington Building, Lexington, KY 40536 0200, USA
    Hematol Oncol Clin North Am 21:115-21. 2007
    ....